RecruitingNCT07369154
Long-term safety of LB-102 in adults with schizophrenia
About this title
Read the official source — NCT07369154This study evaluates the safety of LB-102 for people with schizophrenia.
Medication studyAges 18–65United States
Understand this study
What is this study about?
This study evaluates the safety of LB-102 for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
Adults aged 18–65 with stable schizophrenia who have been taking oral antipsychotic treatment for at least 30 days may be eligible. This Phase 3 study follows participants for 52 weeks while they receive LB-102. It is open-label, so participants and researchers know the treatment being given, and it focuses on longer-term safety and tolerability. It does not compare LB-102 with placebo (an inactive comparison treatment) or establish effectiveness.
- Listed locations
- Chandler and 22 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Participation duration
- The study lasts 52 weeks.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 23, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 900
- Sponsor
- LB Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07369154
- Official title
Show the full official title
A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Chandler · Bentonville · Little Rock
18 more locations
- Anaheim
- Cerritos
- Culver City
- San Diego
- Hollywood
- Miami Lakes
- West Palm Beach
- Atlanta
- Snellville
- Chicago
- Gaithersburg
- St Louis
- Las Vegas
- New York
- Canton
- Philadelphia
- DeSoto
- Richardson
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety of LB-102 for people with schizophrenia.
Who is behind this study?
The study sponsor is LB Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including LB-102.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
